Introduction
The adenosine A 3 receptor is the youngest member discovered in the family of adenosine receptors (A 1 , A 2A , A 2B and A 3 ), all of which belong to class A G protein-coupled receptors (GPCR) [1] . Unlike the other subtypes, the adenosine A 3 receptor is endogenously activated by both adenosine and inosine [2] . Following agonist activation, the receptor causes a decrease in cAMP levels as it primarily couples to G i protein. The adenosine A 3 receptor is widely distributed throughout the body, albeit at low expression levels, and its activation can affect numerous organs, tissues and systems. However, this receptor is overexpressed in inflammatory and cancer cells, reflecting its importance as a therapeutic target and biological marker in these tissues [3, 4] . Moreover, the adenosine A 3 receptor is rapidly internalized within 30 min after agonist exposure [5, 6] . It is unresolved whether receptor desensitization terminates agonist-induced signaling or if this signaling persists after internalization [7] .
Since agonists cause effects of anti-inflammation, cardioprotection and neuroprotection, numerous potent and selective agonists have been extensively studied and developed [8] [9] [10] [11] [12] [13] . Most of these agonists are derivatives of adenosine, with substitutions on the adenine nucleobase or the ribose moiety. In particular, IB-MECA and 2-Cl-IB-MECA are two potent clinical candidates with excellent bioavailability and safety profiles. Selective hA 3 receptor agonists are being evaluated for the treatment of chronic inflammatory diseases (e.g., rheumatoid arthritis or psoriasis), neuropathic pain and cancer (i.e. hepatocellular carcinoma) [14] [15] [16] [17] .
Traditional drug discovery approaches mainly focus on affinity, a parameter that is defined under equilibrium conditions. However, it is emerging that selecting ligands based on their affinity alone, does not necessarily predict in vivo efficacy very well. This may be due to the dynamic conditions in vivo, that often are in contrast to the equilibrium conditions applied in in vitro assays [18] . In fact a ligand's kinetic properties may provide a better indication of how a ligand will perform in vivo [19] . Notably, the parameter of residence time (RT) has been proposed as a more relevant selection criterion. The RT reflects the lifetime of the ligand-receptor complex and can be calculated as the reciprocal of the ligand's dissociation constant [20, 21] .
Although the binding kinetics of hA 3 receptor agonists are occasionally reported [22, 23] , a systematic kinetics analysis yielding structure-kinetics relationships (SKR) has not been conducted. Therefore, we firstly validated the binding kinetics of the prototypical hA 3 receptor agonists (i.e. IB-MECA and 2-Cl-IB-MECA), using radioligand displacement and competition association assays. Then, two series of ribofurano and methanocarba ([3.1.0]bicyclohexane) adenosine derivatives were evaluated for both their affinity (K i ) and kinetics (Kinetic Rate Index (KRI) values, k on , k off , and RTs). This allowed a complete SKR analysis next to a more traditional SAR study. Afterwards, a retrospective evaluation linking residence times and in vivo efficacies was discussed. Last but not least, from a k on -k off -K D kinetic map we divided the agonists into three subgroups, providing a possible direction for the further development of hA 3 R agonists. 0 -N-ethylcarboxamidoadenosine (NECA) was purchased from Sigma-Aldrich (Steinheim, Germany). LUF5501, LUF5505, LUF5500, LUF5506 and LUF5521 have been synthesized and described previously by de Zwart et al. [24] ; LUF5595, LUF5586 and LUF5589 have been described by van Tilburg et al. [25] ; MRS7140, MRS5980, MRS7154, MRS7549, MRS5655, MRS5679, MRS5698, MRS5644, MRS5667 and MRS7294 have been described by Tosh et al. [26] [27] [28] [29] , and MRS3558 by Tchilibon et al. [30] . Adenosine deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein assay reagents were purchased from Pierce Chemical Company (Rockford, IL, USA). Chinese hamster ovary (CHO) cells stably expressing the human adenosine A 3 receptor (CHOhA 3 ) were a gift from Dr. K-N Klotz (University of Würzburg, Germany). All other chemicals were obtained from standard commercial sources and were of analytical grade.
Materials & Methods

Chemicals and reagents
Cell culture and membrane preparation
CHOhA 3 cells were cultured and membranes were prepared and stored as previously described [22] . Protein determination was done through the use of the bicinchoninic acid (BCA) method [31] .
Radioligand equilibrium displacement assays
Membrane aliquots containing $15 lg of CHOhA 3 protein were incubated in a total volume of 100 lL assay buffer (50 mM TrisHCl, 5 mM MgCl 2 , supplemented with 0.01% CHAPS and 1 mM EDTA, pH 7.4) at 10°C for 240 min. Displacement experiments were performed using 6 concentrations of competing agonist in the presence of a final concentration of $10 nM [ 3 H]PSB-11. At this concentration, total radioligand binding did not exceed 10% of that added to prevent ligand depletion. Nonspecific binding (NSB) was determined in the presence of 100 lM NECA. Incubation was terminated by rapid filtration performed on 96-well GF/B filter plates (Perkin Elmer, Groningen, the Netherlands), using a PerkinElmer Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands). After drying the filter plate at 50°C for 30 min, the filter-bound radioactivity was determined by scintillation spectrometry using the 2450 MicroBeta 2 Plate Counter (Perkin Elmer, Boston, MA).
Radioligand competition association assays
The binding kinetics of unlabeled ligands were quantified using the competition association assay based on the theoretical framework by Motulsky and Mahan [32] . The competition association assay was initiated by adding membrane aliquots (15 lg/ well) at different time points for a total of 240 min to a total volume of 100 lL of assay buffer at 10°C with $10 nM [ 3 H]PSB-11 in the absence or presence of a single concentration of competing hA 3 receptor agonists (i.e. at their IC 50 value), and, in some experiments indicated, in the simultaneous presence of 1 mM GTP. Incubations were terminated and samples were obtained as described under Radioligand Displacement Assay. The ''dualpoint" competition association assays were designed as described previously [33] , where in this case the two time points were selected at 20 min (t 1 ) and 240 min (t 2 ).
Data analysis
All experimental data were analyzed using the nonlinear regression curve fitting program GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA). From displacement assays, IC 50 values were obtained by non-linear regression analysis of the displacement curves. The obtained IC 50 values were converted into K i values using the Cheng-Prusoff equation to determine the affinity of the ligands [34] , using a K D value for the radioligand of 1.04 nM at 10°C as determined from radioligand association and dissociation assays, as previously reported [35] . The residence time (RT, in min) was calculated using the equation RT = 1/(60 * k off )), as k off is in s À1 . Association and dissociation rate constants for unlabeled compounds were calculated by fitting the data into the competition association model using ''kinetics of competitive binding": ), L is the radioligand concentration (nM), I is the concentration of the unlabeled competitor (nM), X is the time (s) and Y is the specific binding of the radioligand (DPM). The control curve (without competitor) from competition association assays generates the k 1 value, and the k 2 value was obtained from previous radioligand association and dissociation assays [35] . With that the k 3 , k 4 and B max were calculated, where k 3 represents the k on (M À1 s
À1
) of the unlabeled ligand, k 4 stands for the k off (s À1 ) of the unlabeled ligand and B max equals the total binding (DPM). All competition association data were globally fitted.
Results
3.
1. The effects of GTP on affinities and kinetics of the reference hA 3 receptor agonists IB-MECA and 2-Cl-IB-MECA Firstly, we determined the effects of GTP (1 mM) on both the affinities and binding kinetics of the reference hA 3 receptor ago-nists IB-MECA and 2-Cl-IB-MECA. Under the two different assay conditions (i.e. in the absence or presence of GTP) the affinities of IB-MECA and 2-Cl-IB-MECA were significantly different ( Table 1) . We observed a rightward shift of the displacement curves in the presence of GTP (Fig. 1A, closed symbols) , representing an approx. 3-Fold decrease in affinity for both compounds. Of note, under both experimental conditions, monophasic displacement curves were obtained with pseudo-Hill coefficients close to unity (Table 1) .
Furthermore, there were significant differences between the kinetics of hA 3 receptor agonists tested in the absence or presence of 1 mM GTP. In the competition association assays without GTP, both IB-MECA and 2-Cl-IB-MECA produced a typical ''overshoot", representative of a slower dissociation from the hA 3 receptor than the radioligand [ 3 H]PSB-11 (Fig. 1B) . This overshoot, however, disappeared in the experiments with GTP (Fig. 1C) . Thus, their KRI values were decreased from well-above-unity in the absence of GTP to close-to-unity in the presence of GTP. Table 1 ). Consequently, the calculated RTs in the absence of GTP were longer than the values derived when GTP was present (IB-MECA: 95 min vs 20 min; 2-Cl-IB-MECA 231 min vs 29 min, Table 1 ). Last but not least, the k on values of these two agonists determined under the two assay conditions were similar. Therefore, in order to define a more agonist-relevant receptor interaction, we decided to use the competition association assay in the absence of GTP for the determination of the affinities and the binding kinetics of other unlabeled hA 3 receptor agonists in the remainder of the study.
Binding affinity (K i ) of hA 3 receptor agonists
The binding affinities of 22 human A 3 receptor agonists in total were determined in equilibrium radioligand displacement studies. All agonists were able to concentration-dependently inhibit specific Tables 2 and 3 . The agonists displayed moderate to high binding affinities, ranging from 82 nM for agonist MRS5679 to 0.72 nM for agonist MRS5980, while the reference agonists IB-MECA and 2-Cl-IB-MECA had an affinity of 2.9 and 3.5 nM, respectively.
KRI values of hA 3 receptor agonists
Subsequently, these hA 3 receptor agonists were screened in what is termed a ''dual-point" competition association assay. The specific binding of [ Tables 2 and 3 ). Agonists with a KRI value larger than unity are considered to have a slower dissociation rate, and thus a longer RT, than the radioligand used, i.e. [ 
Binding kinetics of selected hA 3 receptor agonists using the competition association assay
Next, the kinetic binding parameters of selected agonists that had either low or high KRI values were determined using the competition association assay with [ (Tables   2 and 3 ). There was a more pronounced 188-fold difference in dissociation rate constants, in line with the divergent KRI values
The shortest RT agonist, LUF5501, presented a gradually ascending curve in the competition association assays ( Fig. 2A ).
Of note, the dissociation of MRS5679, with the largest KRI value (5.56), was determined as very slow and not readily quantitated under the current method. The very prominent ''overshoot" in the competition association curve was already indicative of a much slower dissociation rate than [ 3 H]PSB-11 ( Fig. 2B) . Notably, a significant correlation between the negative logarithm of the dissociation rate constants for the selected agonists and their KRI values derived from the kinetic assays was obtained (Fig. 3A) , which confirmed that a compound's KRI value is a good predictor for its dissociation rate constant. Besides, a significant correlation was also observed between the agonist affinities (pK i values) determined in equilibrium displacement experiments and their pK D values (''kinetic K D values") derived from competition association experiments, although the pK D values were on average one log unit higher than the pK i values (Fig. 3B ). As to the kinetic rate constants (k on or k off ) of the hA 3 receptor agonists, their association rate constants showed a better correlation with affinity than their dissociation rate constants ( Fig. 3C and D) . Furthermore, a k on -k off -K D ''kinetic map" (Fig. 4 ) was constructed based on the compounds' divergent affinities (expressed as kinetic K D values) and rate constants, yielding a division of these agonists into three different sub-categories: agonists that show k off values in a lower range but due to divergent k on values have various K D values (Group Table 1 The effects of GTP (1 mM) on the affinities and kinetics of hA 3 receptor agonists IB-MECA and 2-Cl-IB-MECA. Table 1 for pK i values and kinetic parameters). Note, t 1 , t 2 are indicated, which are the two time points used in KRI determinations. Table 1 . h N.D. = not determined.
Table 3
Binding affinities and kinetic parameters (KRI, k on , k off , RT and K D ) for (N)-methanocarba derivatives as hA 3 receptor agonists. 3 H]PSB-11 on the hA 3 receptor stably expressed on CHO cell membranes. e RT = 1/(60 * k off ); RT is expressed in min, whereas k off is expressed in s À1 . f K D = k off /k on , expressed in nM. g MRS7294 has a ribofurano ring (see also , respectively, and its RT was calculated as 117 min.
We then examined benzyl substitutions at the N 6 position of the core scaffold, with a methylcarboxamide (-CONHCH 3 ) modification of the 5 0 -position on the ribofuran moiety (MECA, IB-MECA and 2-Cl-IBMECA). MECA had an affinity of 42 nM with a KRI value of 1.24. When iodine was introduced at the 3-position of the benzyl ring, yielding IB-MECA, affinity was strongly increased (2.9 nM vs 42 nM) as well as the KRI value (1.55 vs 1.24); with a further chlorine atom substitution at the C-2 position on the core scaffold (2-Cl-IBMECA) there was no further increase in affinity (3.5 nM vs 2.9 nM), but its KRI value increased significantly (2.02 vs 1.55), which is the largest value in this series ( Table 2 ). For IB-MECA and 2-Cl-IBMECA, the association rate constants were similar ((5.9 ± 0.9) Â ) became faster, even though the compound was still a slowly dissociating agonist compared with the radioligand (KRI: 1.37).
Finally, the effect of the 2-Cl substitution was further confirmed in the comparison between LUF5586 and LUF5589. Their affinities were similar (2.8 nM vs 2.2 nM), but with 2-Cl, LUF5589 had a higher KRI than LUF5586 (1.66 vs 1.30), and the RT of LUF5589 was determined as 138 min. In addition, a larger substituent at the C-2 position (MRS7294) was tolerated with respect to both affinity and kinetics, at least in combination with a small N 6 -methyl substituent. Table 3 summarizes our findings on the series of ring-rigidified methanocarba derivatives that maintain a receptor-preferred North (N) conformation, with the flexible ribose-substituted MRS7294 included once more to allow a comparison. MRS7294, MRS5980, MRS7140, MRS7158 and MRS7154 share a common fragment ((5-chlorothiophen-2-yl)ethynyl) at the C-2-position (R 1 group). MRS7294, the agonist with unmodified ribofuran moiety, served as the starting of the analysis, which had both high affinity (3.7 nM) and a large KRI value (1.63). By competition association experiments its association and dissociation rates were determined as ( (MRS7140) was extended to n-propyl (MRS7154), affinity remained high (2.2 nM), like the KRI value (1.67); both association and dissociation rates of MRS7154 were quite similar to MRS5980 Fig. 3 . The correlations between the negative logarithm of each hA 3 receptor agonist dissociation rate constants (pk off ) and KRI values (A), the A 3 receptor agonist affinity (pK i ) and the ''kinetic K D " (pK D ) (B), logarithm of association rate constants (logk on ) (C) and negative logarithm of dissociation rate constants (pk off ) (D). Data used in these plots are detailed in Tables 2 and 3 . ), leading to a RT for MRS5655 of 909 min. When the phenylethynyl of MRS5655 was 3,4-di-fluorinated as in MRS5698, the affinity was reduced from 3.6 nM (MRS5655) to 9.4 nM (MRS5698), while the KRI value increased significantly from 2.58 (MRS5655) to 4.21 (MRS5698), with both slower association and dissociation rate constants (k on :
), thus extending RT from 909 min to 1961 min. Furthermore, when the phenylethynyl fragment of MRS5655 was expanded to a 4-biphenylethynyl substitution on the R 1 group (MRS5679), the affinity suffered from 3.6 nM (MRS5655) to 82 nM (MRS5679); however, its KRI value increased dramatically from 2.58 to 5.56. This high value rendered the determination of the kinetics profile of MRS5679 impossible. Obviously, from all these compounds we learned there can be a clear dichotomy between affinity and residence time.
When the benzyl substitutions at the N 6 position (R 2 in Table 3) were replaced by a simple monomethyl (i.e. MRS5655 to MRS5644; MRS5679 to MRS5667), their binding affinities to hA 3 receptors were not compromised (MRS5655/MRS5644: 3.6 nM vs 2.4 nM) or even increased (MRS5679/MRS5667: 82 nM vs 4.6 nM), and so were the kinetics profiles of MRS5655 and MRS5644.
The KRI values of MRS5679 and MRS5667 were both at the higher end (5.56 and 3.34).
Discussion
Effects of GTP on agonist binding to the human adenosine A 3 receptor
In the current study, the binding interactions of unlabeled hA 3 receptor agonists were determined in radioligand binding experiments with the reference tritiated antagonist [ 3 H]PSB-11. The favorable binding characteristics of this radioligand served us particularly well in the competition association experiments where robust binding over time could still be measured in the presence of unlabeled ligands, essential for the calculation of the association and dissociation rate constants. It is well known that antagonists occupy a GPCR irrespective of whether it is coupled to a G protein, whereas agonists prefer the G protein-coupled state of the receptor [36] . Addition of GTP to the incubation mixture induces an uncoupling between receptor and available G protein, which leads to a lower apparent receptor affinity for agonists. We confirmed this behavior in our equilibrium displacement experiments, in which the two reference agonists IB-MECA and 2-Cl-IB-MECA had a 3-4-fold lower affinity in the presence of GTP (Fig. 1A, Table 1 ). Interestingly, all displacement curves had pseudo-Hill coefficients of approx. unity ( Table 1 ), suggesting that the agonists recognized one receptor state in both the presence and absence of GTP, most likely a G protein-coupled state (no GTP) or an uncoupled state (with GTP). We then determined the agonist binding kinetics for the two states in subsequent competition association assays by measuring these in the absence or presence of GTP (Fig. 1B) . Interestingly, the association rate constants were identical for the two states (Table 1) . Apparently, the ligand, when approaching the receptor from the extracellular side, is insensitive to the coupling status at the intracellular G protein interface. However, the dissociation kinetics proved to be (significantly) different between the states, up to 8-fold for 2-Cl-IB-MECA ( Table 1 ), suggesting that dissociating from the receptor is influenced by the absence or presence of the G protein. We then performed further experiments in the absence of GTP, as we felt that for the case of the hA 3 receptor this experimental condition provides us information on the more relevant high-affinity agonist binding state of the receptor. The mathematical modeling provided by Motulsky and Mahan [32] does not allow the calculation of two receptor states with corresponding kinetic parameters. Hence, in a number of cases similar to ours it was decided to include GTP in the assays. For the adenosine A 1 receptor, we included GTP in our assays, forcing the receptor to be in one lower affinity, G protein-uncoupled state only; with this restriction, the kinetic parameters of agonists were determined as conveniently as antagonists [37] . Likewise, the team of Charlton included GTP in kinetic assays on the muscarinic M 3 receptor [38] . On the other hand, GTP was excluded in assays on the adenosine A 2A receptor, as agonist affinity at this protein is insensitive to GTP in both equilibrium and kinetics assays [39] .
Methodological aspects of the radioligand binding assays
To ensure an accurate and robust kinetic quantification, experiments were performed at 10°C, as reported and documented previously [35] . Initially, a so-called dual-point competition association assay yielding KRI values for the hA 3 receptor was performed as a ''kinetic screening campaign" to increase throughput in comparison to the traditional, more elaborate, competition association experiments [35] . Although fast kinetics of agonist binding (e.g. LUF5501, Fig. 2A) was determined accurately at a relatively low temperature, the kinetics of one agonist with obviously very slow dissociation characteristics (MRS5679, Fig. 2B ) could not be reliably determined with the Motulsky-Mahan equations. Meanwhile, its large KRI value (5.56) undoubtedly reflects its slow dissociation.
Besides the significant correlation between the agonists' KRI values and dissociation rate constants (Fig. 3A) , the equilibrium K i and kinetic K D values were also well correlated (Fig. 3B ). Despite this correlation there are large discrepancies in values between the equilibrium affinities (K i ) and kinetic K D values. In general, the kinetic pK D values are higher than pK i values, with differences from 0.5 to 2.1 log-unit (LUF5501 and MRS5698), while the short RT agonists have smaller differences than long RT agonists. This phenomenon suggests that the affinities determined in the radioligand displacement studies may not reflect the true affinity of the compounds as many of them have residence times much longer than the (already long) incubation time of 240 min. In fact, this points to a general caveat in end-point assays in which the equilibrium characteristics of the probe, e.g., a radiolabeled or fluorescently tagged compound, determine the assay protocol without further consideration of the same characteristics of the unlabeled ligands to be tested.
Furthermore, there was a significant correlation between k on (k 3 ) and affinity values (K i ) of the agonists, but no relationship was found between k off (k 4 ) and K i (Fig. 3C and D) . Such correlation between affinity and on-rates has been reported in the case of other GPCRs [40] and ion channels [41, 42] . However, in the current study, variations in association rate constants were approximately 10-fold (logk on : 5.0-6.0), much smaller than at the other targets mentioned above. In addition, all the association rates were well below the diffusion limit of around 10 7 M À1 s À1 , which had been observed previously for membrane-bound proteins [43] .
Ligand optimization based on structureÀkinetics relationships (SKRs)
All the agonists examined in the current study have been reported, and the riboside MRS7294 was most recently disclosed as a hA 3 receptor agonist [28] . Most ribofurano derivatives (Table 2) had been synthesized and tested as early as 1994 [44] . The (N)-methanocarba derivatives (Table 3) were explored more recently, showing generally improved affinities over the earlier compounds [26] [27] [28] [29] . Although most of these compounds have been described in the context of structure-affinity relationships (SAR), we reasoned that an extensive structure-kinetics relationships (SKR) analysis is warranted since kinetic profiles are emerging indicators of in vivo functional efficacy [18, 20, 21, 45] .
In the series of ribofurano derivatives (Table 2) , the most outstanding agonist with respect to residence time was 2-Cl-IB-MECA (231 min). The underlying chemical features that prolonged the residence time in the ribofurano series are: i) a chlorine atom at the C2 position (R 1 in Table 2 , IB-MECA vs 2-Cl-IB-MECA, 95 min vs 231 min; LUF5586 vs LUF5589 in KRI: 1.30 vs 1.66), ii) a bulky meta-iodobenzyl substitution at the N 6 position of the adenine nucleobase (R 2 in Table 2 , MECA vs IB-MECA in KRI: 1.24 vs 1.55), and iii) an amide modification at the 5 0 position (R 3 in Table 2 [45, 46] .
More impressive kinetics were observed in the methanocarba series. From a previous study it was concluded that a possible Hbond interaction between the amide modification at the original 5 0 position (-CONHCH 3 ) and residues in the binding pocket of the hA 3 receptor was a key feature of agonist kinetics [47] . Comparing the kinetics of ribofurano MRS7294 and its methanocarba equivalent MRS5980 provides evidence the conformational-constrained (N)-methanocarba moiety as a ribofurano ring substitute adds to the slow dissociation of MRS5980, suggesting this rigid ring system fits even better in the ligand binding pocket. Additionally, the N1 atom on the adenine core is contributing to slow dissociation (1-deza MRS7140 vs MRS5980 in RT: 196 min vs 417 min). The N 6 position in the methanocarba series (R 2 substituent) accepted a small methyl group as avidly as the larger n-propyl (MRS5980 vs MRS7154) and 3-chlorobenzyl substituent (MRS5644 vs MRS5655), with respect to both affinity and kinetics. Apparently, differences in lipophilicity between the N 6 -substituents did not seem to matter either. Data for the R 1 (C2 position) substituent were already commented on in the Results section. It is noteworthy that the 3,4-difluorophenyl fragment contributed to a long residence time of MRS5698, quite similar to the 2,4-difluorophenyl fragment we encountered in A 2A receptor antagonists displaying long residence time [48] . So far the human A 3 receptor has not been crystallized yet, although its most homologous relative, the adenosine A 1 receptor, has [49] . Homology models of the A 3 receptor have been constructed, and their relevance has been recently reviewed and discussed [50] . It appeared that the interaction of the extended and rigid 2-arylethynyl groups at the C-2 position (as in e.g., MRS5679 and MRS5644) with the A 3 receptor required an outward movement of TM2. Although the agonists' path of binding to or dissociation from the A 3 receptor is unknown, one could speculate that such reorganization of TM2 ''locks" the C2-substituted agonist. This reasoning stems from a molecular dynamics simulation and site-directed mutation study of the ligand dissociation pathway from the human adenosine A 2A receptor [51] , for which we used a high resolution crystal structure [52] . It taught us there may be a lid adjacent to the ligand binding pocket retaining the ligand for some time before the compound leaves the receptor. A follow-up study revealed that ligand dissociation correlated with the strength of the salt-bridge between His264 in EL3 and Glu169 in EL2 [53] . It would be interesting to learn whether a similar mechanism exists for the A 3 receptor.
Retrospective evaluation of selected agonists with complete kinetic profiles
IB-MECA (RT = 95 min) and 2-Cl-IB-MECA (RT = 231 min) are two reference full agonists for the hA 3 receptor. Despite numerous reports about their controversial cardioprotection [54, 55] , they have been taken into a series of clinical trials: for IB-MECA, in total 12 completed or planned trials have been reported related to inflammatory conditions (e.g., keratoconjunctivitis sicca, rheumatoid arthritis, psoriasis, uveitis); for 2-Cl-IB-MECA, four trials have been registered for liver diseases (e.g., hepatocellular carcinoma, hepatitis C) [56, 57] . Intuitively one would expect that long residence time hA 3 receptor agonists could be beneficial in chronic diseases, for instance to allow once daily dosing.
More recently, the neuroprotective effect provided by hA 3 receptor agonists has been receiving attention [11, 58] . A number of agonists have been designed and evaluated both in in vitro and in vivo functional experiments, especially for the treatment of chronic neuropathic pain [26, 27, 29] . MRS5698 in particular, having the longest residence time (1961 min) from our research, has been studied extensively in various pre-clinical animal models of neuropathic pain [59] [60] [61] . We, however, hesitate to link the binding kinetics profile of MRS5698 with its in vivo effects, also because issues such as pharmacokinetics and species differences (human/ rodent) may play an important but yet unknown role.
The adenosine A 3 receptor has a peculiar and rapid desensitiza tion/internalization profile in cultured cells [6] . However, the fast desensitization after A 3 agonist exposure under in vitro conditions does not generalize to in vivo pain models. MRS5698 maintained full efficacy over a five-day period, with the drug administered either by daily injection or by an implanted mini-pump to provide a steady state plasma concentration [55] . Prolonged MRS5698 exposure in the rat did not reduce its efficacy, as would be expected from agonist-induced desensitization alone. Thus, additional studies of agonist occupancy of the receptor and subsequent receptor processing are warranted to further explore this interesting target for combatting neuropathic pain.
Kinetic map
Using the association (k on ) and dissociation (k off ) rate constants obtained from competition association experiments (Tables 2 and  3 ), a kinetic map (Fig. 4) was constructed by plotting these values on the y-axis and x-axis, respectively. The dashed diagonal parallel lines represent the kinetically derived K D values (K D = k off /k on ). Out of this map three subgroups emerged, which were divided according to k off values: Group A < Group B < Group C. Obviously, Groups A and C are solely composed of methanocarba derivatives (Fig. 4 , red) and ribofurano derivatives (Fig. 4, blue) , respectively. Group B is a mixture of these two compound classes, with the methanocarba derivatives mainly displaying smaller k off values. Thus, rigidifying the ribose ring with the bicyclic group consistently prolonged the dissociation time. This general division indicates a different mode of receptor-ligand interaction during the binding and unbinding process of the two ligand groups. It also seems there is a clear residence-time ''cliff" between Groups A (having one rigid C2-phenylethynyl or 4-biphenylethynyl group with or without one enlarged N 6 -benzyl group) and B (having multiple enlarged adenine substituents) in the kinetic map.
In each subgroup, agonists exhibit k off values in a similar range, but have different k on values. As a consequence, variation in K D values in each group was observed (Group A: $10-fold; Group B: $100-fold; Group C: $3-fold). Previous SKR studies have primarily focused on optimizing dissociation rates and residence times for designing a kinetically favorable ligand. Yet recently, there has been increasing acknowledgement of the important role association rate constants may play in determining the efficacy of a drug as the result of increased rebinding or increased drug-target selectivity [21, 62] . A kinetic map would thus allow for the selection of compounds with appropriate residence times while exploring the role of association rate constants.
In summary, an agonist-related competition association assay at the hA 3 receptor was validated, and a series of ribofurano and methanocarba derivatives were kinetically profiled for the first time. A k on -k off -K D kinetic map was constructed and subsequently the agonists with complete kinetic profile were divided into three subgroups based on their residence times. Longer residence times were associated with methanocarba (vs. ribose) and enlarged adenine N 6 and C-2 (rigid arylalkynyl) substitutions. We identified agonists with very long residence times, but these may not be the most therapeutically favorable for treating various conditions in view of the fast desensitization of the receptor. Although far from definitive, this study suggests that proper residence times, not necessarily longer than target turnover time, may be vital parameters in the development of hA 3 R agonists for therapeutic use.
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